Disaster Recovery and Business Continuity Planning (BCP) for Pharmaceutical Manufacturing

As hurricane season ramps up, pharmaceutical manufacturers face heightened risks from natural disasters. Facilities located near coasts or in flood zones, dependencies on long, complex supply chains, and the critical need for continuous operations make disaster recovery (DR) and business continuity planning (BCP) essential—not optional. Disturbances like weather extremes, flooding, or wind damage don't just interrupt production: they can lead to drug shortages, compromised product quality, regulatory noncompliance, and even risks to patient safety.

Below is an integrated discussion of why disaster recovery and business continuity matter especially during hurricane season, what recent events have shown, and what pharma companies should do to protect themselves.

Why Disaster Recovery & Business Continuity are Critical in Pharma
Pharmaceutical manufacturing is heavily regulated (GxP, GMP, etc.), and many parts of the process can't tolerate delays or variability.

Key consequences of not having robust plans:

- **Patient safety & supply:** If manufacturing of essential medicines stops, even for a short time, patient care is impacted. Continuity of supply is non-negotiable, particularly for life-saving and life-sustaining therapies subject to broader drug shortages.

- **Regulatory risk:** Regulatory bodies expect companies to have validated systems, traceability, and continuity plans. Gaps can lead to failed audits, warning letters, or worse.

- **Financial cost:** Downtime, spoilage of batches, transport delays, damage to assets—these cost both directly (repairs, replacement) and indirectly (missed sales, extra logistics).

- **Reputation & trust:** Disruptions that affect supply or quality will erode trust with healthcare providers, regulators, patients, and partners

During hurricane season, risks are elevated:

- **Flooding** can damage infrastructure, machinery, or key utilities (power, water).

- **High winds** may damage roofs or disrupt distribution/transportation networks.

- **Storm surge or heavy rain** can overwhelm drainage systems and lead to moisture issues (which in pharma can mean compromised environmental controls).

- **Power outages** threaten temperature-controlled environments, automated monitoring systems, or digital records—of which integrity is essential.

Recent Examples: Lessons from Natural Disasters
Looking at recent years, real-world events illustrate how disruptive these risks can be:

(Continued)

- **Hurricane Helene (September 2024):** Flooding from Helene seriously damaged Baxter International's North Cove facility in North Carolina. That plant supplies approximately 60% of the U.S. supply of sterile IV fluids. The facility had to reduce operations and implement. rationing, which affected hospitals nationwide.
- **Hurricane Milton (also in fall 2024):** Affected Florida, with damage or potential threats to additional IV fluid plants. Plants and distribution centers had to go offline or operate under emergency conditions.
- **Pfizer's tornado damage (2023):** Although not a hurricane, this event serves as a reminder that other natural disasters (tornadoes, earthquakes, wildfires) can also severely impact pharma manufacturing. In North Carolina, a Pfizer plant was heavily damaged, with storage and raw material facilities impacted, causing delays in supply of sterile injectable medications.

These events show that even with some preparedness, gaps in resilience (redundancy, supply chain flexibility, backup systems, and operation restoration planning) can lead to widespread shortages and serious downstream effects.

Key Components of Effective DR & Business Continuity Planning in Pharma
Here are elements pharmaceutical manufacturers should include to build robust plans:

1. Risk Assessment & Business Impact Analysis (BIA)
- Identify critical operations: which products, processes, labs, utilities are essential.
- Model what happens if certain infrastructures fail (power, HVAC, clean room environment, digital systems).
- Determine acceptable downtime and the cost (financial, regulatory, patient safety) of such downtime.

2. Redundancy & Diversification
- Backup power systems (generators, fuel supply) and backup utilities like water and HVAC.
- Alternate manufacturing or fill/finish sites so if one is impacted, others can pick up slack.
- Multiple suppliers and backup sourcing of raw materials and packaging.

3. Infrastructure Resilience
- Physical design considerations: flood barriers, raised foundations, impact-resistant roofs, secure drainage.
- Environmental controls with alarms and fail-safes to protect sterile and temperature-sensitive environments.
- IT infrastructure safeguards: off-site or cloud backups, disaster recovery sites, data mirroring.

4. Operational Continuity & Workforce Planning
- Staff safety protocols and evacuation plans.
- Communication plan: how to alert employees, regulators, customers, and partners during an event.
- Cross-training so multiple employees can run critical processes.

5. Testing, Validation & Regular Review
- Tabletop exercises and full-scale drills of worst-case scenarios (e.g., hurricane + flood + power loss).
- Regular review of recovery time objectives (RTO) and recovery point objectives (RPO) to ensure they align with current risk.

(Continued)

- Audits and updates driven by changes (e.g., climate risk increasing, regulatory changes, expansion of facilities).

6. Regulatory Alignment & Documentation

- Compliance with GMP, regulatory expectations, and sometimes ISO standards (e.g. ISO 22301 for Business Continuity Management).
- Data integrity must be preserved: all records (manual or electronic) must be protected, recoverable, with traceability.

Specific Risks During Hurricane Season & Mitigation

Because hurricanes have predictable seasonal windows, pharma companies in vulnerable regions should pay special attention to:

- **Flooding and storm surge:** confirm site elevation, invest in flood defenses, waterproof critical areas, protect electrical panels.
- **High winds and debris:** ensure building structures meet appropriate codes, protect windows, maintain roofing, secure external elements.
- **Power interruptions:** maintain on-site generators with sufficient fuel reserves; ensure UPS (uninterruptible power supply) for critical equipment and data systems.
- **Transportation/distribution interruption:** identify alternative shipping routes and backup logistics providers; stock strategic safety inventories.

Why It Matters Now

- Climate change is making hurricanes more intense and sometimes more frequent. Even areas that previously had lower risk may see stronger storms.
- Global supply chain fragility means damage in one location (e.g., a single major IV fluid plant) ripples across healthcare systems. The Baxter North Cove example demonstrates how a single plant's impairment can force national-level rationing.
- Regulatory scrutiny is increasing. Regulators expect that companies have credible, documented disaster recovery and continuity plans, including readiness for natural disasters.

Conclusion

As we go through another hurricane season, pharmaceutical manufacturers must ensure that disaster recovery and business continuity are built into their operational DNA—not treated as afterthoughts. Planning beforehand, investing in resilient infrastructure and systems, and regularly testing these plans can mean the difference between a minor disruption and a national or even global shortage of lifesaving medications.

For pharmaceutical companies, it's not just good business—it's about fulfilling a societal mission: to ensure that patients can get the medications they need, where and when they need them, even when Nature tests our systems at their limits.

Kelly Waldron, PhD
Business Unit Manager
kwaldron@valsource.com | 508.380.0243